M. Moore

Inactivated Influenza Vaccines for Prevention of Community-Acquired Pneumonia: The Limits of Using Nonspecific Outcomes in Vaccine Effectiveness Studies

M. Haber, E. Belongia, D. Shay, 2013, Epidemiology.

Fifteen days in December: capture and analysis of Omicron-related travel restrictions

R. Katz, M. Moore, J. Schermerhorn, 2022, BMJ Global Health.

Financing global health security: estimating the costs of pandemic preparedness in Global Fund eligible countries

R. Katz, D. Lowrance, M. Boyce, 2022, BMJ Global Health.

Influenza Vaccine Compliance among Pediatric Asthmatic Patients: What is the Better Method of Notification?

M. Moore, A. Parker, 2006 .

Improving vaccination coverage and offering vaccine to all school-age children allowed uninterrupted in-person schooling in King County, WA: Modeling analysis

J. Schiffer, L. Matrajt, C. Bracis, 2021, medRxiv.

23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

N. French, C. Gilks, E. Janoff, 2000, The Lancet.